Blue Cell Therapeutics ApS: Financial statements 2022
CVR: 39981610
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Blue Cell Therapeutics ApS (CVR 39981610) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 852,135 and a net result of DKK -12,569,961 compared with DKK -14,241,408 the year before. Equity in the 2022 report amounted to DKK 9,911,253. The solvency ratio was 93.3%. The company had 12 employees in the financial year.
- Gross Profit
- DKK 852,135
- Profit/Loss
- DKK -12,569,961
- Equity
- DKK 9,911,253
- Total Assets
- DKK 10,624,661
- Employees
- 12
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 852K | -12.6M | 9.9M | 12 |
| 2021 | - | -844K | -14.2M | 12.5M | 7 |
| 2020 | - | -2.9M | -14M | 9.8M | 2 |
Official annual report
Keep an eye on Blue Cell Therapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Blue Cell Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -843,696, and the net result was DKK -14,241,408.
As of February 3, 2022, André Rafal Rogaczewski has left the board of directors of Blue Cell Therapeutics ApS.
About Blue Cell Therapeutics ApS
Blue Cell Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Regenerative Therapeutics IVS. The management consists of Søren Paludan Sheikh. The board consists of Olav Hellebø (chair), Anella Rogaczewski, Michael Ulveman and Ole Vahlgren. The company is owned by ANDRÉ ROGACZEWSKI HOLDING II ApS and SPSheikh Holding ApS. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK -5,780,568 and a net result of DKK -21,221,120 compared with DKK -15,189,850 the year before. Equity in the 2025 report amounted to DKK -8,126,690.